The paradoxical rise in overall and cancer-specific mortality despite increased detection and treatment of renal cell carcinoma (RCC) is termed "treatment disconnect." We reassess this phenomenon by evaluating impact of missing data and rising incidence on mortality trends.
M ore than 62,000 men and women will be diagnosed with kidney cancer in the United States in 2016 alone, and over 14,000 will die of their disease. 1 Cross-sectional imaging has led to a rise in incidence over the last 3 decades, [2] [3] [4] leading to a subsequent increase in surgical interventions. 4 On the basis of the assumption that early detection and treatment of early stage renal cell carcinoma (RCC) should result in improved survival outcomes, one would expect a decline in population-based mortality rates over time. However, examination of national overall and cancerspecific mortality trends using Surveillance, Epidemiology, and End Results (SEER) data have documented a paradoxical rise in mortality rates when accounting for stage and size migration. 4 Indeed, this phenomenon, termed "treatment disconnect," has dramatically impacted clinical and policy perspectives in the management of kidney cancer. 5 "Treatment disconnect" has been attributed in part to length and lead-time biases, and to the fact that the absolute number of patients with ultimately lethal lesions has not diminished. However, some investigators have noted discrepancies in cancer mortality rates between whole and restricted datasets, 6 and others have demonstrated that changes in incidence can have significant impact on mortality data interpretation. 7 As such, legitimacy of "treatment disconnect" deserves reassessment. Thus, our objective was to examine the impact of missing size data and adjustment for rising incidence on overall and cancer-specific mortality trends for patients with RCC using national tumor registry data.
METHODS
The SEER program of the National Cancer Institute assembles information on cancer incidence, local treatment, and survival in the United States. The SEER program registries collect data on patient demographics, including primary tumor site, tumor morphology and stage at diagnosis, first course of treatment, and follow-up for survival. Registries participating in the SEER program capture approximately 97% of incident cases. 8 We identified all patients with an incident kidney cancer diagnosis from 1983 to 2011 from the 9 original SEER registries (Metropolitan Atlanta, Connecticut, Metropolitan Detroit, Hawaii, Iowa, New Mexico, San FranciscoOakland, Seattle-Puget Sound, Utah). On the basis of International Classification of Diseases for Oncology, Second Edition site code C64.9, we restricted the cohort to RCC histology codes (8032, 8041, 8240, 8260, 8270, 8290, 8310, 8312, 8317, 8318, 8319, 8320, 8960, 8963, and 8966), as well as behavior codes 2 and 3 as described in the original report. All tumor stages were included for analysis.
Demographic and cancer-specific data, including age at diagnosis, race, sex, tumor laterality, organ-confined status, and tumor histology were extracted. All covariates were treated as categorical variables with the exception of age, which was treated as a continuous variable. Restricted to 1983-2011 (years with available tumor size data), patients were sorted into 4 tumor size categories (< 2, 2-4, >4-7, and >7 cm) as previously described. 4 Patients with missing size data were categorized independently. Patient demographic and clinical characteristics were compared between size groups independently, and then between those with and without available tumor size data using analysis of variance and w 2 tests. Age-adjusted annual mortality rates (overall and cancer-specific) for RCC were calculated by determining the number of deaths each year, dividing by the corresponding mid-year population estimates provided by SEER, and multiplying by 100,000. Rates were age adjusted to the 2000 US population using direct adjustment methods. Data were extracted using SEER*STAT software [reference: SEER*-STAT Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 8.1.5] and analyses were performed using STATA Version 13 software (StataCorp LP, College Station, TX). Missing size data were estimated using multiple imputations (IVE ware). Differences between observed and imputed mortality rates when considering observed and imputed tumor size were compared between size categories using linear regression in which we included main effects and interaction terms for year and imputation status (observed vs. imputed rate). In estimating the models to test for differences between observed and imputed rates, we weighted the regressions by the inverse of the variance of each estimated rate, as is appropriate when using summarized data, 9 and used robust SE.
In separate analyses, we estimated the overall mortality rate for all comers from 1983 to 2011, irrespective of tumor size, after adjustment for prior cumulative incidence using ridge regression, an estimation technique used to attain a substantial reduction in variance while increasing the stability of the coefficients. We chose to use ridge regression, since year and incidence rates are strongly correlated; that is, the incidence rates change at an almost completely linear rate over time. The ridge regression is able to provide stable estimates in the presence of such collinearity. 10 For prior adjustment, we first summed the current year and the previous 10-year incidence rate to get a cumulative incidence rate. We then entered the cumulative incidence rate as a covariate in the ridge regression using a restricted cubic spline with 4 knots. 11 Differences between the mortality rates estimated using observed cumulative incidence (ie, incidence varying over time) and those estimated using incidence adjusted to the 2011 rate (ie, holding incidence constant at 2011 rates) were assessed using linear regression with bootstrap SE with 10,000 iterations. 12 We also examined the mortality over incidence (MOI) ratio as another metric for investigating the relationship of yearly mortality compared with same year incidence. 13 
RESULTS
A total of 78,891 patients met inclusion criteria from 1973 to 2011, of which 70,212 were diagnosed in 1983 or later. Of those diagnosed from 1983, 10.4% had missing data. Demographic and clinical data stratified by tumor size is presented in Table 1 . Significant differences were observed between size groups with respect to age, sex, laterality, stage, histology, and grade (all P-values = < 0.001). Age-adjusted kidney cancer incidence has uniformly increased across age categories over the study period (Fig. 1) .
Corresponding with increasing rates of surgeries performed (data not presented), the proportion of patients with missing tumor data (21.6% in 1983 to 4.2% in 2011, P < 0.001) significantly decreased over the study period. Patients with missing tumor size significantly differed from patients with documented tumor size with respect to age, race, laterality, stage, histology, and grade (Table 1) . Patients with missing size data tended to be older with more advanced stage (or unstaged with missing histology).
When evaluating temporal changes in age-adjusted overall mortality between 1983 and 2011, significant increases for all sizes were noted for <2 cm tumors (0.11-0.61, P < 0.001), 2-4 cm tumors (0.54-2.16, P < 0.001), >4-7 cm tumors (1.38-2.19, P < 0.001), and >7 cm tumors (1.93-2.28, P < 0.001) ( Fig. 2A) . In comparison, small but statistically significant increases in age-adjusted cancer-specific mortality for tumors <2 cm (0.05-0.14, P < 0.001) and 2-4 cm tumors (0.19-0.37, P < 0.001), but not for >4-7 cm tumors (0.92-0.72, P = 0.45), and >7 cm tumors (1.54-1.40, P = 0.98) were demonstrated (Fig. 2B) .
Compared with observed rates, following missing data imputation, significant attenuation in the change in overall mortality rate per 100,000 US population from 1983 to 2011 were noted ( Similarly, comparing observed to imputed rates, significant differences in the cancer-specific morality rates were noted (Fig. 2D) For the entire cohort irrespective of tumor size, holding the incidence of kidney cancer constant at 2011 rates, the temporal increase from 1983 to 2011 in overall mortality for all patients was attenuated (P < 0.001 for test of difference in slope) when comparing model estimates using historical incidence (3.8-7.3) and adjusted to 2011 incidence (5.3-6.9) rates (Fig. 3A) , suggesting that rapidly rising incidence may also influence reported overall mortality trends. Comparing estimates using historical incidence (2.6-2.9) and estimated (3.1-2.6) cancer-specific mortality rates (Fig. 3B) , no significant differences were observed (P = 0.97). The MOI metric for each year was also plotted, demonstrating a reduction in kidney cancer-specific mortality over the study period (Fig. 4) .
DISCUSSION
To better understand the "treatment disconnect" phenomenon, our aim was to investigate factors that affect interpretation of epidemiologic data for patients diagnosed with renal cell carcinoma, which has wide applicability across the spectrum of cancer care. Specifically, we hypothesized that missing tumor size data, and the rapidly increasing incidence of RCC, affect interpretation of RCC mortality trends using SEER data. 4 We found that imputation of missing size data significantly attenuates the previously documented rise in both overall and cancer-specific mortality rates when stratified by tumor size. Furthermore, when adjusting for 2011 cumulative incidence, the temporal increase in overall mortality was significantly less than unadjusted estimates, irrespective of tumor size. Tracking the MOI over time, a recently suggested metric to normalize mortality rates, 13 further supported our findings that the rise in RCC mortality is likely significantly smaller than previously described and its precise quantification is markedly confounded by rising RCC incidence. Over the last 3 decades, kidney cancer incidence has increased uniformly across age categories in the SEER dataset, and has been predominantly due to increased detection of localized disease (Fig. 1) . 3 Similar trends have been observed in European registry databases, albeit granular data have demonstrated regional variations in detection rates. 14 Although the reasons are multifactorial, increased performance of routine abdominal imaging is the most likely cause. 15 However, while the rates of renal surgery have risen simultaneously with increased tumor detection, conflicting RCC survival and mortality trends have been reported, and it remains unclear if the dramatic increase in early detection and treatment over the past 2 decades has meaningfully impacted survival in patients with kidney cancer. As overdiagnosis of clinically insignificant malignancy, along with receipt of unneeded treatment as well as its attendant risks, are arguably the most important harms associated with early cancer detection, 16 this uncertainty has led to the reassessment of contemporary practice patterns for incidentally diagnosed lesions. 17 Tumor size remains one the most influential clinical factor impacting provider treatment decisions in the management of kidney cancer. 18 Not recorded in SEER until 1983, findings from our study demonstrate that tumor size information was missing in 22.7% of cases in the SEER cohort, and that the proportion of patients with missing tumor size is inversely proportional to the rate of renal procedures performed. As a result, the proportion of cases with missing tumor data early in the study period significantly outweighed that of the latter period. Imputing tumor size for these cases significantly attenuated the rise in mortality for tumors when stratified by tumor size. Reasons for this are multifactorial, but may reflect the fact that patients early in the study period presented with larger more aggressive tumors, given the well described stage migration towards earlier stage disease due to the increased use of routine abdominal imaging in the later years of the cohort. 15 These findings are significant, suggesting that the "treatment disconnect" phenomenon that has been previously described when evaluating SEER data segregated by tumor size may be largely explained by accounting for missing size data. 4, 6 Rapid concurrent rises in tumor incidence and mortality have been demonstrated in other tumor types, most notably in prostate cancer cohorts following the advent of prostate-specific antigen screening; however, kinetics of disease progression and intensity of screening markedly differ between malignancies. 19 A rapid peak followed by a decline in mortality after the initiation of cancer screening can be influenced by lead and length time biases. The influence of increasing incidence on mortality rates can significantly influence data interpretation, yet this fact has not received significant attention in the urologic literature. 7, 13, 19 When examining overall and cancer-specific mortality rates per 100,000 persons, a rapid influx of newly documented incidental cancer diagnoses of uncertain clinical significance concurrently increases the pool of patients eligible to die with (not likely from) that given cancer. This phenomenon artificially raises the mortality rate in a given population, resulting in a form of allocation bias. For instance, if data collection is initiated in a particular year, only patients diagnosed in that year are captured as dying from kidney cancer. Meanwhile the following year a larger pool of patients, those diagnosed in the initial year and the following year, become "eligible" for being indexed as dying with the disease, thus significantly confounding data interpretation. As such, our analyses holding the cumulative incidence of kidney cancer constant significantly attenuated the observed increase in overall survival rates over time, while cancerspecific survival remained essentially unchanged.
Although the impact of lack of recurrence data, reliance on death certificate cause of death to determine cancer-specific survival, and lack of comorbidity assessment significantly impacts the use of SEER data for unbiased comparative effectiveness assessment, 20, 21 these limitations are likely less important for measuring general population level trends in mortality over time that are blinded to treatment type. 22, 23 To evaluate the influence of rising incidence on observed mortality over time, we elected to use ridge regression. Although this approach avoids the exaggerated impact on variance observed with linear regression analyses, the interpretation of the actual magnitude of measured effects remains limited using this methodology due to inherent biases.
Pitfalls and challenges associated with understanding underpinnings of population-based survival, mortality, and incidence data trends have been described. 19 Supplementary Table A (Supplemental Digital Content 1, http://links.lww. com/MLR/B291) summarizes expected data trends under various ideal scenarios if they were to occur nonconcurrently. Real-world data represents an amalgam of concurrent processes and as such, as our analyses demonstrate, are extremely challenging to interpret. Some investigators have proposed that normalizing mortality by incidence may provide insights into progress in cancer management. 13 We have included MOI analysis for patients with RCC, which indeed suggests improvement in treatment effect over time (Fig. 4) . Nevertheless, these data are likely overly optimistic given that MOI analyses are disproportionally affected by overdiagnosis phenomena, which undoubtedly plague kidney cancer management. 7, 13 In conclusion, our analyses suggest that missing data and rising incidence rates contribute substantially to the "treatment disconnect" phenomenon observed when examining kidney cancer mortality rates using SEER data. As these adjusted changes in mortality appear to be substantively less pronounced than previously demonstrated, "treatment disconnect" should not temper our enthusiasm for definitive treatment in appropriate candidates. We hope that our work puts into better focus the limitations of existing datasets and serves as a catalyst for improving epidemiologic data gathering and interpretation. Nevertheless, as the evidence base to support shared decision making for treatment of kidney cancer is limited, we will continue to rely on tumor registry data to evaluate changes in mortality trends as the treatment paradigm evolves. However, these trends must be contextualized clinically and should be used to inform clinical trial development as opposed to direct evidence to implement changes in practice.
